Perioperative characteristics, histologic diagnosis, complications, and outcomes of dogs undergoing percutaneous drainage, sclerotherapy or surgical management of intrarenal cystic lesions: 18 dogs (2004–2021)

Table 1 Outcome of 5 dogs that underwent PCD

Dog number	Histologic diagnosis	Previous treatment	Clinical signs related to ICL at FU^a	Resolution of preprocedural clinical signs at last FU^a	Progression in size of treated ICL(s) at last FU imaging^a	Azotemia pre-procedure	Azotemia on FU biochemistry^a	Additional treatment performed	Dead, alive, LTFU post treatment
5	Cystadenocarcinoma	Sclerotherapy (289 days)	Yes, PU/PD, vomiting, hyporexia (236 days)	N/A	NP	NP	Yes (238 days)	Laparoscopic deroofing (241 days)	Died, unknown cause (443 days; 732 days post index treatment)
6	Transitional cell carcinoma with cyst formation	NP	Not available	N/A	92.5% its original size (14 days)	No	NP	Ureteronephrectomy (29 days)	Euthanized, progressive renal dysfunction (1245 days post index treatment)
9	NP	NP	No (42 days)	N/A	108.1% its original size (42 days)	No	NP	No	LTFU (42 days post index treatment)
10	Renal adenoma	NP	Not available	N/A	6 cm (original size not available) (8 days after second PCD)	No	No	Yes, repeat PCD (39 days); sclerotherapy (57 days); laparoscopic deroofing and omentalization (81 days)	Alive (406 days post index treatment)
16	NP	NP	Not available	N/A	100% its original size (78 days following second PCD)	Yes	Yes, progressively deteriorating (71 & 78 days after first & second PCD)	Yes PCD repeated twice (71 &149 days)	Euthanized due to hemoabdomen following 3rd PCD (Euthanized same day of 3rd PCD; 149 days post index treatment)

Days presented in parentheses are calculated from the date of the PCD
FU follow-up, LTFU lost to follow-up, PU/PD polyuria/polydipsia, N/A not applicable, NP not performed
^a Denotes date of last follow-up either after PCD or until the date of revision treatment

ISSN: 1746-6148